The Value of Pre-Screening in the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease Trial

The Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease (ADAD) trial evaluates the anti-amyloid-β antibody crenezumab in cognitively unimpaired persons who, based on genetic background and age, are at high imminent risk of clinical progression, and provides a powerful test...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Prev Alzheimers Dis
Main Authors: Rios-Romenets, S., Giraldo-Chica, M., López, H., Piedrahita, F., Ramos, C., Acosta-Baena, N., Muñoz, C., Ospina, P., Tobón, C., Cho, W., Ward, M., Langbaum, J.B., Tariot, P.N., Reiman, E.M., Lopera, F.
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5987758/
https://ncbi.nlm.nih.gov/pubmed/29405233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14283/jpad.2017.44
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares